Budesonide

Summary

Budesonide (CHEMBL1370) is an approved small-molecule anti-inflammatory drug (ATC A07EA06) targeting NR3C1, NR3C2, and PGR; indicated across 48 conditions including allergic rhinitis and chronic obstructive pulmonary disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: A07EA06 (+3 more)
• Targets: 3 (NR3C1, NR3C2, PGR)
• Indications: 48 conditions
• Clinical trials: 385
• Chemistry: 430.5 Da · C25H34O6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1370
Name	Budesonide
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	5281004
ChEBI	CHEBI:3207
ATC	A07EA06, R03BA02, D07AC09, R01AD05
Molecular formula	C25H34O6
Molecular weight	430.5
InChIKey	VOVIALXJUBGFJZ-KWVAZRHASA-N

SMILES: CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@@]5([C@H]4[C@H](C[C@@]3([C@@]2(O1)C(=O)CO)C)O)C

IUPAC name: (1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-propyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one

ChEBI definition: A glucocorticoid steroid having a highly oxygenated pregna-1,4-diene structure. It is used mainly in the treatment of asthma and non-infectious rhinitis and for treatment and prevention of nasal polyposis.

Pharmacological roles (ChEBI): anti-inflammatory drug, bronchodilator agent, drug allergen.

Also known as: Aircort, Budeflam aquanase, Budelin novolizer, Budenofalk, Budesonida, Budesonide, Budesonide component of airsupra, Budesonide component of breztri, Budesonide component of symbicort, Budesonide component of uceris, Cortiment, Duoresp spiromax

Patent coverage: 18,468 distinct patent families (72,936 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
NR3C1	Glucocorticoid receptor	Agonist	7.42	0.9%	P04150
NR3C2	Mineralocorticoid receptor	Agonist	7.85	0%	P08235
PGR	Progesterone receptor	Agonist	7.15	0.1%	P06401

Broader ChEMBL bioactivity targets: 20 (assay-derived). Sample: Interleukin-5, Interleukin-5, Nuclear receptor ROR-gamma, Survival motor neuron protein, Thrombopoietin, ATP-binding cassette sub-family C member 4, Androgen receptor, Mineralocorticoid receptor, Glucocorticoid receptor, Progesterone receptor, Muscarinic acetylcholine receptor M1, Androgen receptor, Matrix metalloproteinase-9, Nuclear factor NF-kappa-B p105 subunit, Glucocorticoid receptor, Cytochrome P450 3A4, 3-hydroxyacyl-CoA dehydrogenase type-2, Interleukin-5 receptor subunit alpha, ATP-binding cassette sub-family C member 3, Bile salt export pump.

Bioactivity

ChEMBL activities: 33 potent at pChembl ≥ 5 of 49 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
NR3C1	9.3	IC50	0.5	nM	CHEMBL_ACT_18140876
NR3C1	9.1	AC50	0.8	nM	CHEMBL_ACT_25175803
NR3C1	9.05	IC50	0.9	nM	CHEMBL_ACT_28902740
NR3C1	8.89	Ki	1.3	nM	CHEMBL_ACT_18503311
NR3C1	8.8	IC50	1.57	nM	CHEMBL_ACT_18140934
NR3C1	8.7	EC50	2	nM	CHEMBL_ACT_19129298
NR3C1	8.7	EC50	2	nM	CHEMBL_ACT_22450491
NR3C1	8.69	Ki	2.03	nM	CHEMBL_ACT_7616862
P06536	8.54	IC50	2.9	nM	CHEMBL_ACT_1196122
NR3C1	8.46	EC50	3.5	nM	CHEMBL_ACT_18503378
NR3C1	8.42	IC50	3.8	nM	CHEMBL_ACT_18141075
NR3C1	8.35	IC50	4.47	nM	CHEMBL_ACT_7616861
NR3C2	8.32	EC50	4.8	nM	CHEMBL_ACT_18503399
NR3C1	8.3	AC50	5	nM	CHEMBL_ACT_25175802
PGR	8.05	AC50	9	nM	CHEMBL_ACT_25223001
THPO	8	Potency	10	nM	CHEMBL_ACT_4809410
THPO	8	Potency	10	nM	CHEMBL_ACT_5070421
NR3C1	7.91	EC50	12.4	nM	CHEMBL_ACT_6390731
NR3C2	7.85	IC50	14	nM	CHEMBL_ACT_18141061
PGR	7.55	IC50	28	nM	CHEMBL_ACT_18141096
PGR	7.49	AC50	32.1	nM	CHEMBL_ACT_25204382
NFKB1	7.25	Potency	56.2	nM	CHEMBL_ACT_3671962
NFKB1	7.25	Potency	56.2	nM	CHEMBL_ACT_4585244
AR	6.16	AC50	694.4	nM	CHEMBL_ACT_25203449
P15207	6.15	IC50	710	nM	CHEMBL_ACT_18141068
P15207	5.96	Ki	1090	nM	CHEMBL_ACT_7618338
SMN1	5.95	Potency	1122	nM	CHEMBL_ACT_3893325
NR3C1	5.92	AC50	1200	nM	CHEMBL_ACT_25116168
P15207	5.79	IC50	1635	nM	CHEMBL_ACT_7618337
P15207	5.77	AC50	1700	nM	CHEMBL_ACT_25187424
MMP9	5.7	IC50	1989	nM	CHEMBL_ACT_7618285
CYP3A4	5.1	Potency	7943	nM	CHEMBL_ACT_4957392
CYP3A4	5.1	Potency	7943	nM	CHEMBL_ACT_5026749

Target pathways

Aggregated over 3 target gene(s): NR3C1, NR3C2, PGR.

Top Reactome pathways

18 total, by targets touching each:

Pathway	Targets	Genes
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand	3	NR3C1, NR3C2, PGR
Nuclear Receptor transcription pathway	3	NR3C1, NR3C2, PGR
SUMOylation of intracellular receptors	3	NR3C1, NR3C2, PGR
Nuclear signaling by ERBB4	1	PGR
Cellular responses to stress	1	NR3C2
SUMOylation	1	NR3C2
SUMO E3 ligases SUMOylate target proteins	1	NR3C2
Metabolism of proteins	1	NR3C2
Post-translational protein modification	1	NR3C2
PTK6 Expression	1	NR3C1
Regulation of RUNX2 expression and activity	1	NR3C1
Cellular responses to stimuli	1	NR3C2
Estrogen-dependent gene expression	1	PGR
FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes	1	NR3C1
Potential therapeutics for SARS	1	NR3C1
Regulation of NPAS4 gene transcription	1	NR3C1
Developmental Lineage of Mammary Gland Luminal Epithelial Cells	1	PGR
Developmental Lineage of Mammary Gland Alveolar Cells	1	PGR

Dominant GO biological processes

GO term	Targets
regulation of DNA-templated transcription	3
regulation of transcription by RNA polymerase II	3
signal transduction	3
nuclear receptor-mediated steroid hormone signaling pathway	3
positive regulation of transcription by RNA polymerase II	2
negative regulation of transcription by RNA polymerase II	1
regulation of gluconeogenesis	1
chromatin organization	1
apoptotic process	1
chromosome segregation	1
glucocorticoid metabolic process	1
response to wounding	1
gene expression	1
microglia differentiation	1
adrenal gland development	1

Indications & clinical

Indications

12 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
allergic rhinitis	4	MONDO:0011786	EFO:0005854
chronic obstructive pulmonary disease	4	MONDO:0005002	EFO:0000341
ulcerative colitis	4	MONDO:0005101	EFO:0000729
Crohn disease	4	MONDO:0005011	EFO:0000384
seasonal allergic rhinitis	4	MONDO:0005324	EFO:0003956
obstructive lung disease	4	MONDO:0002267	HP:0006536
IgA glomerulonephritis	4	MONDO:0005342	EFO:0004194
perennial allergic rhinitis	4	MONDO:0024332	EFO:1001417
pulmonary emphysema	4	MONDO:0004849	EFO:0000464
chronic bronchitis	4	MONDO:0005607	EFO:0006505
asthma	4	MONDO:0004979	MONDO:0004979
esophageal disorder	4	MONDO:0003749	EFO:0009544

29 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
eosinophilic esophagitis	3	MONDO:0005361	EFO:0004232
sinusitis	3	MONDO:0005961	EFO:0007486
altitude sickness	3	MONDO:0006625	EFO:1000782
obstructive sleep apnea syndrome	3	MONDO:0007147	EFO:0003918
collagenous colitis	3	MONDO:0000703	EFO:1001293
lymphocytic colitis	3	MONDO:0000704	EFO:1001294
microscopic colitis	3	MONDO:0000702	EFO:1001295
primary biliary cholangitis	3	MONDO:0005388	EFO:1001486
respiratory system disorder	3	MONDO:0005087	EFO:0000684
graft versus host disease	3	MONDO:0013730	MONDO:0013730
severe acute respiratory syndrome	3	MONDO:0005091	MONDO:0100096
bronchopulmonary dysplasia	3	MONDO:0019091	MONDO:0019091
proctocolitis	3	MONDO:0024278	MONDO:0021736
nasal cavity polyp	2	MONDO:0006314	EFO:1000391
proctitis	2	MONDO:0005538	EFO:0005628
melanoma	2	MONDO:0005105	EFO:0000756
autoimmune hepatitis	2	MONDO:0016264	EFO:0005676
allergic bronchopulmonary aspergillosis	2	MONDO:0015243	EFO:0007140
bronchiolitis obliterans syndrome	2	MONDO:0015265	EFO:0007183
acute respiratory distress syndrome	2	MONDO:0006502	EFO:1000637
diarrheal disease	2	MONDO:0001673	HP:0002014
status asthmaticus	2	MONDO:0004766	EFO:0008590
breast neoplasm	2	MONDO:0021100	MONDO:0007254
lung neoplasm	2	MONDO:0021117	MONDO:0008903
plasma cell myeloma	2	MONDO:0009693	EFO:0001378
allergic disease	2	MONDO:0005271	MONDO:0005271
inflammatory bowel disease	2	MONDO:0005265	EFO:0003767
radiation pneumonitis	2	MONDO:0043919	MONDO:0043919
sclerosing cholangitis	1	MONDO:0018646	EFO:0004268

7 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 385.

Phase distribution

Phase	Trials
PHASE3	135
PHASE4	83
Not specified	56
PHASE2	51
PHASE1	35
PHASE2/PHASE3	13
PHASE1/PHASE2	6
EARLY_PHASE1	6

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01225913	PHASE4	RECRUITING	Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
NCT03615742	PHASE4	RECRUITING	Diesel Exhaust Induces Glucocorticoid Resistance
NCT04342039	PHASE4	ACTIVE_NOT_RECRUITING	Epigenetic Health Benefits of Budesonide
NCT06209047	PHASE4	RECRUITING	Bronchoscopic Levofloxacin, Gentamicin, or Sham for Acute Exacerbation of Bronchiectasis
NCT06334575	PHASE4	RECRUITING	Molecular Signatures Associated With Response to ICS Treatment in Patients With COPD Stratified by Eosinophil Levels
NCT06571942	PHASE4	RECRUITING	Effect of the Inhaled Triple Therapies Over the Small Airway in Biomass Exposure
NCT06841406	PHASE4	RECRUITING	Budesonide as a Treatment for Functional Dyspepsia
NCT07073950	PHASE4	RECRUITING	A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation
NCT00092092	PHASE4	COMPLETED	Study of Montelukast and Its Effect on Lower Leg Growth in Children With Asthma (MK-0476-254)
NCT00189436	PHASE4	COMPLETED	Effect of Nebulized Budesonide and Oral Corticosteroids on Wheezing Episode Relapse in Children
NCT00202189	PHASE4	COMPLETED	Effects of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease (COPD)
NCT00242411	PHASE4	COMPLETED	MONO: Symbicort® Single Inhaler Therapy and Conventional Best Standard Treatment for the Treatment of Persistent Asthma in Adolescents and Adults
NCT00272753	PHASE4	COMPLETED	Effect of Budesonide / Formoterol Combination in Repeated AMP Provocations
NCT00338910	PHASE4	COMPLETED	Pharmacokinetic Interaction Study Between Budesonide and Metronidazole in Healthy Volunteers
NCT00379028	PHASE4	COMPLETED	Airway Clearance Study
NCT00380484	PHASE4	COMPLETED	Short- and Long Term Growth in Children With Asthma
NCT00463866	PHASE4	COMPLETED	Local Phase 4 Pan-European SMART Study
NCT00471809	PHASE4	TERMINATED	Childhood Asthma Research and Education (CARE) Network Trial - Montelukast or Azithromycin for Reduction of Inhaled Corticosteroids in Childhood Asthma (MARS)
NCT00479739	PHASE4	COMPLETED	CONCEPT: A 1-Year Comparison Of A Stable Dose Of SERETIDE® Inhaler With An Adjustable Maintenance Dose Of SYMBICORT® Inhaler. SERETIDE® Inhaler is a Trademark of GSK Group of Companies. SYMBICORT® Inhaler is a Trademark of Astra Zeneca.
NCT00487773	PHASE4	COMPLETED	Effect of Different Doses of Budesonide on Markers of Bone Metabolism in Children With Asthma
NCT00489853	PHASE4	COMPLETED	Evaluation of Efficacy on Exercise Tolerance of Symbicort (Budesonide/Formoterol) Compared to Placebo and Oxis in Patients With Severe COPD
NCT00490243	PHASE4	COMPLETED	Effect of Different Anti-Asthmatic Treatments on Lung Function and on Exercise-Induced Bronchoconstriction in Children With Asthma
NCT00522782	PHASE4	COMPLETED	Effect of Budesonide on Exhaled Nitric Oxide in Asthmatic Children
NCT00560586	PHASE4	COMPLETED	Nasal Budesonide in Children With Rhinitis and/or Mild Obstructive Sleep Apnea Syndrome
NCT00584636	PHASE4	WITHDRAWN	Pulmicort Respules on Relapse Rates After Treatment in the ED
NCT00624429	PHASE4	UNKNOWN	A Pilot Study Involving an Asthma Management Program for Inner-city Early Head Start Children
NCT00641212	PHASE4	COMPLETED	Children, Perennial Allergic Rhinitis (PAR), l-t Growth
NCT00641446	PHASE4	COMPLETED	Varicella Vaccination With Pulmicort
NCT00641914	PHASE4	COMPLETED	Inhaled Steroid Treatment as Regular Therapy in Early Asthma
NCT00661973	PHASE4	WITHDRAWN	Inhaled Corticosteroids on Airway Smooth Muscle in Asthma
NCT00702325	PHASE4	COMPLETED	Phase4/Symbicort® Versus Pulmicort Flexhaler® in African Americans
NCT00716963	PHASE4	COMPLETED	Does Fluticasone Propionate Reduce the Late Allergic Reaction When the Drug is Given Post-allergen?
NCT00733473	PHASE4	COMPLETED	Nebulized Budesonide for Children Who Are Hospitalized for Acute Wheezing
NCT00860938	PHASE4	COMPLETED	Predictor for an Additional Benefit of Inhaled Corticosteroid in Patients Treated With Tiotropium for COPD
NCT00867737	PHASE4	UNKNOWN	Onset of Action of Advair Hydrofluoroalkane (HFA) 115/21 in Comparison to Symbicort Pressurised Metered-Dose Inhalers (pMDI) 160/4.5 Measured by Impulse Oscillometry (IOS)
NCT00883532	PHASE4	UNKNOWN	Prevention of Chronic Lung Disease (CLD) in Preterm Infants
NCT00915538	PHASE4	COMPLETED	Comparing Bronchodilation of Symbicort With and Without Valved Holding Chamber (Aerochamber Plus)
NCT00996697	PHASE4	COMPLETED	Differential Trough Effects of ‘Triple Therapy’ on Pulmonary Function in Chronic Obstructive Pulmonary Disease (COPD)
NCT01070888	PHASE4	TERMINATED	Trial on the Effect of Budesonide/Formoterol and Inhaled Budesonide Alone on Exercise-Induced Asthma
NCT01186653	PHASE4	COMPLETED	Effect on Adrenal Function of Budesonide Versus Fluticasone in Chronic Obstructive Pulmonary Disease (COPD)
NCT01253473	PHASE4	COMPLETED	Symbicort in Airway Predominant Chronic Obstructive Pulmonary Disease (COPD)
NCT01270256	PHASE4	COMPLETED	NasoNeb Delivery of an Intranasal Steroid
NCT01340118	PHASE4	COMPLETED	Improvement of FeNO and FEF25-75 After Inhaled Corticosteroid Treatment of Asthma
NCT01397890	PHASE4	COMPLETED	Efficacy and Tolerability of Symbicort as an add-on Treatment to Spiriva Compare With Spiriva Alone in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT01520688	PHASE4	COMPLETED	Effect of Flovent Discus vs QVAR vs Pulmicort Flexhaler on Short Term Growth
NCT01712854	PHASE4	TERMINATED	Effects of Symbicort on the Ventilatory Kinematics
NCT01760304	PHASE4	TERMINATED	Changes in Cardiac Function in COPD Patients After Administration of Budesonide/Formoterol (Symbicort®) Versus Placebo
NCT01846962	PHASE4	COMPLETED	Dietetic Versus Topical Steroids for Pediatric Eosinophilic Esophagitis
NCT01865500	PHASE4	COMPLETED	Two Different Dosages of Nebulized Steroid Versus Parenteral Steroid in the Management of COPD Exacerbations
NCT01912872	PHASE4	TERMINATED	Study to Assess the Efficacy and Safety of Omalizumab Treatment on ICS Reduction for Severe IgE-mediated Asthma
NCT02002715	PHASE4	COMPLETED	Therapeutic Effect of Different Treatment Course With Inhaled Corticosteroids in Eosinophilic Bronchitis Patients
NCT02019758	PHASE4	COMPLETED	Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis
NCT02055352	PHASE4	COMPLETED	Study to Evaluate Efficacy/Safety of Combination Budesonide/Indacaterol vs Fluticasone/Salmeterol in Patients With COPD
NCT02357277	PHASE4	WITHDRAWN	The Effects of Inhaled Glucocorticoids on the Postmenopausal Skeleton
NCT02504801	PHASE4	UNKNOWN	Efficacy of Nebulized Pulmicort Respules in Primary Lung Cancer Patients With COPD
NCT02526758	PHASE4	UNKNOWN	Small Airways Evaluation and Treatment
NCT02533505	PHASE4	COMPLETED	Phase IV O2 Consumption Study in COPD Patients.
NCT02546297	PHASE4	UNKNOWN	Comparisons of Inhaled LAMA or LAMA+LABA or ICS+LABA for COPD With Bronchiectasis
NCT02574975	PHASE4	UNKNOWN	Assessment of Airway Responsiveness and Treatment Efficacy in Asthmatics
NCT02696850	PHASE4	COMPLETED	The Impact Of The Addition Of Budesonide To Low-Pressure, High-Volume Saline Sinus Irrigation For Chronic Rhinosinusitis
NCT02771717	PHASE4	UNKNOWN	Low Exhaled NO and ICS in Suspected Asthma
NCT02934945	PHASE4	UNKNOWN	Treatment Efficacy of Budesonide/Formoterol in Cough Variant Asthma and Typical Asthma Patients
NCT03028701	PHASE4	COMPLETED	Assessment of Bronchodilator Efficacy of Formoterol/Budesonide 12/400 mcg Via Discair in COPD
NCT03034005	PHASE4	COMPLETED	The RECONSTRUCT Study - Reconstructing Disease Mechanisms in Asthma
NCT03219866	PHASE4	TERMINATED	Nebulizer Versus Dry Powdered Inhalers for Chronic Obstructive Pulmonary Disease (COPD)
NCT03275415	PHASE4	COMPLETED	Intratracheal Budesonide/Surfactant Prevents BPD
NCT03315052	PHASE4	WITHDRAWN	Budesonide for Immunosuppression After Liver Transplantation to Reduce Side Effects
NCT03369847	PHASE4	COMPLETED	Inhaled Steroids for Pediatric Asthma at Pediatric Emergency Medicine Discharge
NCT03478683	PHASE4	COMPLETED	A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT03478696	PHASE4	COMPLETED	A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT03521063	PHASE4	UNKNOWN	Efficacy of Adding Budesonide to Poractant Alfa to Prevent Bronchopulmonary Dysplasia.
NCT03551197	PHASE4	UNKNOWN	Change of Lung Function After Exercise in Patients With Chronic Obstructive Pulmonary Disease
NCT03924635	PHASE4	COMPLETED	An Exploratory Study to Characterise Changes in Airway Inflammation, Symptoms, Lung Function and Reliever Use in Adult Asthma Patients
NCT04132570	PHASE4	COMPLETED	A Study of Intranasal Budesonide Aqueous Spray for Treatment of Rhinitis During Periods of High Airborne Pollution
NCT04171180	PHASE4	UNKNOWN	The Efficacy of Budesonide/Formoterol in Cough Variant Asthma
NCT04355637	PHASE4	COMPLETED	Inhaled Corticosteroid Treatment of COVID19 Patients With Pneumonia
NCT04520230	PHASE4	COMPLETED	Three Treatment of Chronic Obstructive Pulmonary Disease Patients
NCT05152355	PHASE4	COMPLETED	Clinical Equivalence of Budesonide HFA MDI Versus Budesonide Turbuhaler in Mild to Moderate Chinese Asthma Patients
NCT05444543	PHASE4	COMPLETED	Cycling of Topical Steroids for Treatment of EoE (Eosinopilic Esophagitis)
NCT05970263	PHASE4	WITHDRAWN	IKANOS: Breztri Maintenance Versus Any Non-Triple Inhaled Therapy After Hospitalization for a COPD Exacerbation in the US
NCT06158893	PHASE4	UNKNOWN	Comparison of Preoperative Inhaled Budesonide With Salbutamol on the Respiratory Adverse Effects in Children Undergoing Tonsillectomy
NCT06563102	PHASE4	COMPLETED	Study to Investigate Changes in Airway Inflammation, Symptoms, and Rescue Therapy Utilization With AIRSUPRA Compared to Albuterol as Needed in Adults With Mild Asthma
NCT06905483	PHASE4	COMPLETED	Comparative Effects of Triple Inhaled Therapy With Budesonide/Glycopyrronium/Formoterol Versus Fluticasone Furoate/Umeclidinium/Vilanterol on Small Airway Disease in COPD Patients: A Randomized Crossover Study
NCT04727424	PHASE3	RECRUITING	Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild Symptoms
NCT05509933	PHASE3	RECRUITING	Budesonide Prophylaxis for Engraftment Syndrome After Hematopoietic Cell Transplantation
NCT05562466	PHASE3	RECRUITING	A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma
NCT05831566	PHASE3	RECRUITING	Expertise Asthma COPD Program with Digital Support
NCT06429475	PHASE3	RECRUITING	Anti-Inflammatory Reliever South Africa
NCT06471257	PHASE3	RECRUITING	A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma
NCT06473779	PHASE3	ACTIVE_NOT_RECRUITING	Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.
NCT06596252	PHASE3	RECRUITING	Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE
NCT06719622	PHASE2/PHASE3	ENROLLING_BY_INVITATION	Evaluation of the Efficacy of Local Budesonide Treatment in Children with Crohn’s Disease Located in the Esophagus And/or Stomach And/or Duodenum
NCT06895460	PHASE3	NOT_YET_RECRUITING	A Trial on the Treatment of Bronchial Asthma With Budesonide Formoterol Combined With Immune Modulators (Staphylococcus and Neisseria Tablets)
NCT07318350	PHASE3	NOT_YET_RECRUITING	Study of Formoterol 6 mcg/Fluticasone 125 mcg by Eurofarma Laboratórios S.A. Versus Alenia® 6 mcg/200 mcg in Patients With Asthma (FORASMA)
NCT00000575	PHASE3	COMPLETED	Childhood Asthma Management Program (CAMP) Phases I (Trial), II (CAMPCS), III (CAMPCS/2), and IV (CAMPCS/3)
NCT00128739	PHASE3	COMPLETED	Treatment of Gastro-Intestinal and/or Hepatic Graft Versus Host Disease With Budesonide in Patients Following Peripheral Blood Stem Cell Transplantation
NCT00139165	PHASE3	UNKNOWN	Long-Term Treatment of Collagenous Colitis With Budesonide
NCT00180050	PHASE3	COMPLETED	Budesonide Treatment for Lymphocytic Colitis
NCT00180076	PHASE3	COMPLETED	Budesonide for Maintenance Treatment of Collagenous Colitis
NCT00180089	PHASE3	COMPLETED	Budesonide for Prevention of Acute Gastrointestinal GVHD Following Allogenic Stem Cell Transplantation

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

345 molecules share ≥1 primary target. Top 100 by shared-target count:

Molecule	Source	Status	Shared targets
ENZALUTAMIDE	ChEMBL + PubChem	Phase 4 (approved)	NR3C1, NR3C2, PGR
EPLERENONE	ChEMBL + PubChem	Phase 4 (approved)	NR3C1, NR3C2, PGR
FLUDROCORTISONE	ChEMBL + PubChem	Phase 4 (approved)	NR3C1, NR3C2, PGR
DEXAMETHASONE	ChEMBL	Phase 4 (approved)	NR3C1, NR3C2, PGR
FLUTICASONE FUROATE	ChEMBL	Phase 4 (approved)	NR3C1, NR3C2, PGR
FLUTICASONE PROPIONATE	ChEMBL	Phase 4 (approved)	NR3C1, NR3C2, PGR
HYDROCORTISONE	ChEMBL	Phase 4 (approved)	NR3C1, NR3C2, PGR
HYDROCORTISONE BUTYRATE	ChEMBL	Phase 4 (approved)	NR3C1, NR3C2, PGR
MEDROXYPROGESTERONE	ChEMBL	Phase 4 (approved)	NR3C1, NR3C2, PGR
MIFEPRISTONE	ChEMBL	Phase 4 (approved)	NR3C1, NR3C2, PGR
PREDNISOLONE	ChEMBL	Phase 4 (approved)	NR3C1, NR3C2, PGR
PROGESTERONE	ChEMBL	Phase 4 (approved)	NR3C1, NR3C2, PGR
SPIRONOLACTONE	ChEMBL	Phase 4 (approved)	NR3C1, NR3C2, PGR
ASOPRISNIL	ChEMBL	Phase 3	NR3C1, NR3C2, PGR
METRIBOLONE	ChEMBL	Phase 2	NR3C1, NR3C2, PGR
ONAPRISTONE	ChEMBL	Phase 2	NR3C1, NR3C2, PGR
STANOLONE	ChEMBL	Phase 2	NR3C1, NR3C2, PGR
TUROFEXORATE ISOPROPYL	ChEMBL	Phase 2	NR3C1, NR3C2, PGR
Fidaxomicin	ChEMBL + PubChem	Phase 4 (approved)	NR3C1, PGR
FULVESTRANT	ChEMBL + PubChem	Phase 4 (approved)	NR3C1, PGR
PODOFILOX	ChEMBL + PubChem	Phase 4 (approved)	NR3C1, PGR
REGORAFENIB	ChEMBL + PubChem	Phase 4 (approved)	NR3C1, PGR
ALCLOMETASONE DIPROPIONATE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
AMCINONIDE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
BECLOMETHASONE DIPROPIONATE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
BENZBROMARONE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
BETAMETHASONE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
BETAMETHASONE DIPROPIONATE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
BETAMETHASONE VALERATE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
BUTOCONAZOLE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
CANDESARTAN CILEXETIL	ChEMBL	Phase 4 (approved)	NR3C1, PGR
CANRENONE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
CHLORMADINONE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
CICLESONIDE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
CLOBETASOL PROPIONATE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
DANAZOL	ChEMBL	Phase 4 (approved)	NR3C1, PGR
DAUNORUBICIN	ChEMBL	Phase 4 (approved)	NR3C1, PGR
DEFLAZACORT	ChEMBL	Phase 4 (approved)	NR3C1, PGR
DESOGESTREL	ChEMBL	Phase 4 (approved)	NR3C1, PGR
DESONIDE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
DESOXIMETASONE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
DESOXYCORTICOSTERONE PIVALATE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
DIETHYLSTILBESTROL	ChEMBL	Phase 4 (approved)	NR3C1, PGR
DIFLORASONE DIACETATE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
DOXORUBICIN	ChEMBL	Phase 4 (approved)	NR3C1, PGR
DROSPIRENONE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
ECONAZOLE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
EFAVIRENZ	ChEMBL	Phase 4 (approved)	NR3C1, PGR
ESTRADIOL	ChEMBL	Phase 4 (approved)	NR3C1, PGR
ESTRIOL	ChEMBL	Phase 4 (approved)	NR3C1, PGR
ETHINYL ESTRADIOL	ChEMBL	Phase 4 (approved)	NR3C1, PGR
EXEMESTANE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
FELODIPINE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
FLUNISOLIDE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
FLUOCINOLONE ACETONIDE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
FLUOCINONIDE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
FLUOROMETHOLONE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
FLUOXYMESTERONE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
FLURANDRENOLIDE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
HALCINONIDE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
HYDROXYPROGESTERONE CAPROATE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
IDARUBICIN	ChEMBL	Phase 4 (approved)	NR3C1, PGR
ISOCONAZOLE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
LOTEPREDNOL ETABONATE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
MASOPROCOL	ChEMBL	Phase 4 (approved)	NR3C1, PGR
MEDRYSONE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
MEGESTROL	ChEMBL	Phase 4 (approved)	NR3C1, PGR
MESTRANOL	ChEMBL	Phase 4 (approved)	NR3C1, PGR
METHYLPREDNISOLONE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
METHYLTESTOSTERONE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
MICONAZOLE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
MITOTANE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
MOMETASONE FUROATE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
MONTELUKAST	ChEMBL	Phase 4 (approved)	NR3C1, PGR
NISOLDIPINE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
NOMEGESTROL	ChEMBL	Phase 4 (approved)	NR3C1, PGR
NORETHINDRONE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
NORGESTIMATE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
OXYMETHOLONE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
PONATINIB	ChEMBL	Phase 4 (approved)	NR3C1, PGR
PREDNICARBATE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
PREDNISONE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
QUINESTROL	ChEMBL	Phase 4 (approved)	NR3C1, PGR
RIMEXOLONE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
SIMVASTATIN	ChEMBL	Phase 4 (approved)	NR3C1, PGR
TAMOXIFEN	ChEMBL	Phase 4 (approved)	NR3C1, PGR
TESTOSTERONE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
TESTOSTERONE PROPIONATE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
TIBOLONE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
TIOCONAZOLE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
TOLCAPONE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
TRIAMCINOLONE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
TRIAMCINOLONE ACETONIDE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
TROGLITAZONE	ChEMBL	Phase 4 (approved)	NR3C1, PGR
ZAFIRLUKAST	ChEMBL	Phase 4 (approved)	NR3C1, PGR
BALCINRENONE	ChEMBL	Phase 3	NR3C1, NR3C2
CANRENOATE	ChEMBL	Phase 3	NR3C1, PGR
CYPROTERONE	ChEMBL	Phase 3	NR3C1, PGR
ETHISTERONE	ChEMBL	Phase 3	NR3C1, PGR
OTILONIUM BROMIDE	ChEMBL	Phase 3	NR3C1, PGR